⌘K
t
| Date | 28 Feb 2025 |
| Time | 07:00:10 |
| Category | Miscellaneous |
| ID | 7920Y |
28 February 2025
Cardiogeni PLC
("Cardiogeni" or the "Company")
Director's Dealings
Cardiogeni (AQSE: CGNI), a UK clinical stage biotechnology company founded by 2007 Nobel Laureate Sir Martin Evans to advance novel heart failure medicines through human trials, announces that Darrin Disley, Executive Chairman of Cardiogeni has purchased a total of 152,205 ordinary shares of the Company, the details of which are set out in the notification below.
Following the purchase, Darrin Disley will hold 2,816,017 ordinary shares representing 3.30% of Cardiogeni's issued share capital.
The directors of Cardiogeni accept responsibility for this announcement.
This announcement, including the notification below, is made in accordance with the requirements of the UK Market Abuse Regulation.
For further information please contact:
|
Cardiogeni PLC |
|
|
Dr Darrin M Disley OBE, Executive Chairman |
Via First Sentinel |
|
First Sentinel Corporate Finance Limited Corporate Adviser |
|
|
Brian Stockbridge Gabrielle Cordeiro
|
+44 (0) 7858 888007 |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|||||||||||||||||
|
a) |
Name |
Darrin Disley |
||||||||||||||||
|
2. |
Reason for the Notification |
|||||||||||||||||
|
a) |
Position/status |
Executive Chairman |
||||||||||||||||
|
b) |
Initial notification / Amendment |
Initial notification |
||||||||||||||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||||||||||||
|
a) |
Name |
Cardiogeni PLC
|
||||||||||||||||
|
b) |
LEI |
9845000F8F59ATZD8F92 |
||||||||||||||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||||||||||||
|
a) |
Description of the Financial instrument, type of instrument |
Ordinary shares |
||||||||||||||||
|
|
ISIN |
GB00BTBLFC12 |
||||||||||||||||
|
b) |
Nature of the transaction |
Purchase of shares |
||||||||||||||||
|
c) |
Price(s) and volume(s) |
|
||||||||||||||||
|
d) |
Aggregated information: · Aggregated volume · Price |
Aggregated volume: 152,205 Price: £0.197 |
||||||||||||||||
|
e) |
Date of the transaction |
25/02/2025 to 27/02/2025 |
||||||||||||||||
|
f) |
Place of the Transaction |
Aquis Exchange Growth Market (AQSE) |
||||||||||||||||